OIG: CMS could lower Medicare payment for 15 Part B drugs
![hhs-health-and-human-services-seal](/sites/default/files/styles/900x400/public/2018-04/hhs-health-and-human-services-seal.jpg?itok=tMTKQqdS)
In a report this week, the Department of Health and Human Services’ Office of Inspector General identified 15 drug codes that in third-quarter 2022 met the Centers for Medicare & Medicaid Services’ criteria for substituting a lower Medicare price for certain Part B drugs. This means CMS may substitute either the widely available market price or 103% of the Average Manufacturers Price, whichever is less, when pricing these drugs, rather than using Average Sales Price plus 6%. The report does not identify the 15 drug codes.
Related News Articles
Headline
The Centers for Medicare & Medicaid Aug. 15 announced it negotiated lower prices with drug makers for 10 high-cost, sole-source drugs, with the new prices…
Headline
The AHA, joined by five other national hospital associations, Aug. 14 filed an amicus brief urging the Supreme Court to correct the Department of Health and…
Headline
The AHA Aug. 13 commented to the Medicare Payment Advisory Commission in anticipation of the commission’s 2024-2025 cycle. The AHA urged MedPAC to carefully…
Headline
More than 46 million prior authorization requests were submitted to Medicare Advantage insurers in 2022, according to KFF analysis released Aug. 6 examining…
Headline
The AHA along with the Federation of American Hospitals, America’s Essential Hospitals and the Association of American Medical Colleges July 29 filed an amicus…
Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…